IL98372A - ((1-arylpyrrolidin-2-yl)methyl) piperazine derivatives their preparation and their application in therapeutics - Google Patents

((1-arylpyrrolidin-2-yl)methyl) piperazine derivatives their preparation and their application in therapeutics

Info

Publication number: IL98372A
Authority: IL; Israel
Prior art keywords: formula; process according; derivatives; solvent; group
Prior art date: 1990-06-07

Application number

IL9837291A

Other languages

English (en)

Other versions

IL98372A0 (en

Original Assignee

Sythelabo S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-07

Filing date

1991-06-04

Publication date

1996-01-31

1991-06-04 Application filed by Sythelabo S A filed Critical Sythelabo S A

1992-07-15 Publication of IL98372A0 publication Critical patent/IL98372A0/xx

1996-01-31 Publication of IL98372A publication Critical patent/IL98372A/en

Links

125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims abstract description 14
238000002360 preparation method Methods 0.000 title claims description 6
239000003814 drug Substances 0.000 title 1
150000004885 piperazines Chemical class 0.000 title 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 42
239000002253 acid Substances 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 12
238000011282 treatment Methods 0.000 claims abstract description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
208000012902 Nervous system disease Diseases 0.000 claims abstract description 4
208000025966 Neurological disease Diseases 0.000 claims abstract description 4
125000005843 halogen group Chemical group 0.000 claims abstract description 4
150000007513 acids Chemical class 0.000 claims abstract description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 35
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 34
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 16
238000000034 method Methods 0.000 claims description 16
150000001408 amides Chemical class 0.000 claims description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
239000002904 solvent Substances 0.000 claims description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 10
239000012280 lithium aluminium hydride Substances 0.000 claims description 9
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 8
150000004820 halides Chemical class 0.000 claims description 6
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 5
-1 tri ethylaluminium amine Chemical class 0.000 claims description 5
206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000012442 inert solvent Substances 0.000 claims description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
208000026680 Metabolic Brain disease Diseases 0.000 claims description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
208000037863 aminoacidopathy Diseases 0.000 claims description 2
239000000010 aprotic solvent Substances 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
230000001537 neural effect Effects 0.000 claims description 2
230000003955 neuronal function Effects 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims 1
125000001033 ether group Chemical group 0.000 claims 1
238000011065 in-situ storage Methods 0.000 claims 1
125000003944 tolyl group Chemical group 0.000 claims 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
101150047265 COR2 gene Proteins 0.000 abstract 1
101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
239000000203 mixture Substances 0.000 description 26
239000000243 solution Substances 0.000 description 26
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
239000007787 solid Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
229910052786 argon Inorganic materials 0.000 description 8
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical class [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
229910010084 LiAlH4 Inorganic materials 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
230000002490 cerebral effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000002198 insoluble material Substances 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
230000002253 anti-ischaemic effect Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000003480 eluent Substances 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
LNXYALHPFVINEA-UHFFFAOYSA-N (1-phenylpyrrolidin-2-yl)-piperazin-1-ylmethanone Chemical compound C1CNCCN1C(=O)C1CCCN1C1=CC=CC=C1 LNXYALHPFVINEA-UHFFFAOYSA-N 0.000 description 2
OAODJZIUEOXVGO-UHFFFAOYSA-N 1-[(1-phenylpyrrolidin-2-yl)methyl]piperazine Chemical class C1CNCCN1CC1CCCN1C1=CC=CC=C1 OAODJZIUEOXVGO-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
208000010496 Heart Arrest Diseases 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
230000002082 anti-convulsion Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
210000001627 cerebral artery Anatomy 0.000 description 2
210000003710 cerebral cortex Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002920 convulsive effect Effects 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
ZZMSDLWVAMNVOD-JTQLQIEISA-N (2s)-1-phenylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C1=CC=CC=C1 ZZMSDLWVAMNVOD-JTQLQIEISA-N 0.000 description 1
ZHFGJUZQBXWHST-UHFFFAOYSA-N 1-(2-phenylethyl)-4-[(1-phenylpyrrolidin-2-yl)methyl]piperazine Chemical compound C1CN(CC2N(CCC2)C=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 ZHFGJUZQBXWHST-UHFFFAOYSA-N 0.000 description 1
LKUAPSRIYZLAAO-UHFFFAOYSA-N 1-(2-phenylethyl)piperazine Chemical compound C1CNCCN1CCC1=CC=CC=C1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 1
IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010038669 Respiratory arrest Diseases 0.000 description 1
206010043994 Tonic convulsion Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000006887 Ullmann reaction Methods 0.000 description 1
GUZOGIBURQURFB-UHFFFAOYSA-N [4-(2-phenylethyl)piperazin-1-yl]-(1-phenylpyrrolidin-2-yl)methanone Chemical compound C1CN(CCC=2C=CC=CC=2)CCN1C(=O)C1CCCN1C1=CC=CC=C1 GUZOGIBURQURFB-UHFFFAOYSA-N 0.000 description 1
GUZOGIBURQURFB-QFIPXVFZSA-N [4-(2-phenylethyl)piperazin-1-yl]-[(2s)-1-phenylpyrrolidin-2-yl]methanone Chemical compound C([C@H]1C(=O)N2CCN(CCC=3C=CC=CC=3)CC2)CCN1C1=CC=CC=C1 GUZOGIBURQURFB-QFIPXVFZSA-N 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
238000009835 boiling Methods 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000006264 debenzylation reaction Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000009297 electrocoagulation Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
MXXIDFFOQXWVBM-UHFFFAOYSA-N ethyl 4-(1-phenylpyrrolidine-2-carbonyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)C1N(C=2C=CC=CC=2)CCC1 MXXIDFFOQXWVBM-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003434 inspiratory effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
XDZRVULZULGWLN-UHFFFAOYSA-N phenyl-[4-[(1-phenylpyrrolidin-2-yl)methyl]piperazin-1-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)N(CC1)CCN1CC1CCCN1C1=CC=CC=C1 XDZRVULZULGWLN-UHFFFAOYSA-N 0.000 description 1
239000000047 product Substances 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

IL9837291A 1990-06-07 1991-06-04 ((1-arylpyrrolidin-2-yl)methyl) piperazine derivatives their preparation and their application in therapeutics IL98372A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9007067A FR2663026B1 (fr)	1990-06-07	1990-06-07	Derives de [(1-arylpyrrolidin-2-yl) methyl] piperazine, leur preparation et leur application en therapeutique.

Publications (2)

Publication Number	Publication Date
IL98372A0 IL98372A0 (en)	1992-07-15
IL98372A true IL98372A (en)	1996-01-31

Family

ID=9397358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9837291A IL98372A (en)	1990-06-07	1991-06-04	((1-arylpyrrolidin-2-yl)methyl) piperazine derivatives their preparation and their application in therapeutics

Country Status (21)

Country	Link
US (1)	US5192763A (de)
EP (1)	EP0461012B1 (de)
JP (1)	JPH04235958A (de)
KR (1)	KR100188902B1 (de)
AT (1)	ATE104662T1 (de)
AU (1)	AU634391B2 (de)
CA (1)	CA2043981A1 (de)
CS (1)	CS173691A3 (de)
DE (1)	DE69101740T2 (de)
DK (1)	DK0461012T3 (de)
ES (1)	ES2054460T3 (de)
FI (1)	FI97055C (de)
FR (1)	FR2663026B1 (de)
HU (1)	HU209620B (de)
IE (1)	IE64688B1 (de)
IL (1)	IL98372A (de)
NO (1)	NO177931C (de)
NZ (1)	NZ238431A (de)
PL (1)	PL165187B1 (de)
PT (1)	PT97885B (de)
ZA (1)	ZA914339B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1245712B (it) *	1991-04-09	1994-10-14	Boehringer Mannheim Italia	Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
FR2684374B1 (fr) *	1991-12-02	1995-05-19	Synthelabo	Derives substitues de 1-[(1-arylpyrrolidin-2-yl)methyl]piperazine, leur preparation et leur application en therapeutique.
IT1255704B (it) *	1992-09-30	1995-11-10	Boehringer Mannheim Italia	Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3250771A (en) *	1962-12-17	1966-05-10	Geigy Chem Corp	5-monocarbocyclic aryl-n-lower alkyl-2-pyrrolidine carboxylic acid, esters, amides and derivatives thereof
GB1428493A (en) *	1973-05-02	1976-03-17	Science Union & Cie	Heterocyclic amides processes for their preparation and pharma ceutical compositions containing them
US5063242A (en) *	1989-04-21	1991-11-05	Warner-Lambert Company	7-((substituted)amino)-8-((substituted)carbonyl)-methylamino-1-oxaspiro[4,5]decanes as diuretics antiinflammatory, and cerebrovascular agents

1990
- 1990-06-07 FR FR9007067A patent/FR2663026B1/fr not_active Expired - Fee Related
1991
- 1991-06-03 AT AT9191401431T patent/ATE104662T1/de not_active IP Right Cessation
- 1991-06-03 DK DK91401431.1T patent/DK0461012T3/da active
- 1991-06-03 DE DE69101740T patent/DE69101740T2/de not_active Expired - Fee Related
- 1991-06-03 EP EP91401431A patent/EP0461012B1/de not_active Expired - Lifetime
- 1991-06-03 ES ES91401431T patent/ES2054460T3/es not_active Expired - Lifetime
- 1991-06-04 IL IL9837291A patent/IL98372A/en not_active IP Right Cessation
- 1991-06-06 ZA ZA914339A patent/ZA914339B/xx unknown
- 1991-06-06 CA CA002043981A patent/CA2043981A1/en not_active Abandoned
- 1991-06-06 PL PL91290572A patent/PL165187B1/pl unknown
- 1991-06-06 IE IE194191A patent/IE64688B1/en unknown
- 1991-06-06 JP JP3134761A patent/JPH04235958A/ja active Pending
- 1991-06-06 NO NO912168A patent/NO177931C/no not_active IP Right Cessation
- 1991-06-06 PT PT97885A patent/PT97885B/pt not_active IP Right Cessation
- 1991-06-06 FI FI912733A patent/FI97055C/fi active
- 1991-06-06 NZ NZ238431A patent/NZ238431A/xx unknown
- 1991-06-06 US US07/710,711 patent/US5192763A/en not_active Expired - Fee Related
- 1991-06-06 CS CS911736A patent/CS173691A3/cs unknown
- 1991-06-06 HU HU911895A patent/HU209620B/hu not_active IP Right Cessation
- 1991-06-06 AU AU78196/91A patent/AU634391B2/en not_active Ceased
- 1991-06-07 KR KR1019910009395A patent/KR100188902B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU7819691A (en)	1991-12-12
HU209620B (en)	1994-09-28
ZA914339B (en)	1992-03-25
ATE104662T1 (de)	1994-05-15
PT97885A (pt)	1992-03-31
FR2663026A1 (fr)	1991-12-13
NO177931B (no)	1995-09-11
DE69101740T2 (de)	1994-10-20
HU911895D0 (en)	1991-12-30
IL98372A0 (en)	1992-07-15
KR100188902B1 (ko)	1999-06-01
IE911941A1 (en)	1991-12-18
NO912168L (no)	1991-12-09
NO177931C (no)	1995-12-20
US5192763A (en)	1993-03-09
DK0461012T3 (da)	1994-09-12
EP0461012B1 (de)	1994-04-20
HUT58070A (en)	1992-01-28
NZ238431A (en)	1992-09-25
EP0461012A1 (de)	1991-12-11
DE69101740D1 (de)	1994-05-26
PT97885B (pt)	1998-10-30
AU634391B2 (en)	1993-02-18
JPH04235958A (ja)	1992-08-25
ES2054460T3 (es)	1994-08-01
FI97055B (fi)	1996-06-28
CA2043981A1 (en)	1991-12-08
FI912733L (fi)	1991-12-08
PL165187B1 (pl)	1994-11-30
KR920000751A (ko)	1992-01-29
FR2663026B1 (fr)	1992-08-07
NO912168D0 (no)	1991-06-06
FI97055C (fi)	1996-10-10
FI912733A0 (fi)	1991-06-06
IE64688B1 (en)	1995-08-23
CS173691A3 (en)	1992-02-19
PL290572A1 (en)	1992-02-10

Legal Events

Date	Code	Title
1996-07-23	FF	Patent granted
1997-11-20	KB	Patent renewed
2002-02-10	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
KR101432112B1 (ko)	2014-08-21	도파민 ｄ3 수용체 리간드로서의 신규 카보닐화된 (아자)사이클로헥산
JP3593037B2 (ja)	2004-11-24	ピロリジン誘導体ｃｃｒ−３受容体アンタゴニスト
US4954502A (en)	1990-09-04	1-indolyalkyl-4-(substituted-pyridinyl)piperazines
DE19952146A1 (de)	2001-06-07	Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1546099B1 (de)	2008-12-31	3,6-disubstituierte azabicyclo-3.1.0 hexan-derivate als muscarinische rezeptorantagonisten
JPH11501640A (ja)	1999-02-09	５−ｈｔ▲下４▼拮抗作用を有するジ−置換１，４−ピペリジンエステル類及びアミド類
DE4204270A1 (de)	1993-11-04	Benzimidazolylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EA029097B1 (ru)	2018-02-28	Совместные кристаллы и соли ингибиторов ccr3
JPH10504298A (ja)	1998-04-28	環状尿素誘導体、これらの化合物を含む医薬組成物及びそれらの調製方法
SK132498A3 (en)	1999-08-06	Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
DE60316180T2 (de)	2008-05-29	Aminoalkoxyindol-derivate als 5-ht6-rezeptorliganden zur bekämpfung von zns-krankheiten
JP2010522156A (ja)	2010-07-01	５−ＨＴ２ｃ作動薬としてのピリミド［４，５−ｄ］アゼピン誘導体
CZ294233B6 (cs)	2004-11-10	Acylaminoalkenylenamidové deriváty, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
CA2354213C (en)	2010-04-27	N-triazolylmethyl-piperazine compounds with neurokinin-receptor antagonist activity
HU196194B (en)	1988-10-28	Process for producing new 1-4 disubstituted piperazines and pharmaceuticals comprising the compounds
CZ342397A3 (cs)	1998-03-18	Piperazinové deriváty jako antagonisté neurokininu
DE69735811T2 (de)	2006-12-28	Piperazinoderivate als neurokinin-antagonisten
IE922090A1 (en)	1992-12-30	2-(1-piperidyl)ethanol derivatives, their preparation and¹their therapeutic application
JP2009503048A (ja)	2009-01-29	尿路機能障害を治療するためのｍｃ４ｒ作動薬
WO2011091410A1 (en)	2011-07-28	Trpv4 antagonists
IL98372A (en)	1996-01-31	((1-arylpyrrolidin-2-yl)methyl) piperazine derivatives their preparation and their application in therapeutics
JP2003518108A (ja)	2003-06-03	ニューロキニン・アンタゴニストとしてのα−アリールエチルピペラジン誘導体
JPS6335573A (ja)	1988-02-16	新規置換ピリド〔２，３−ｂ〕〔１，４〕ベンゾジアゼピン−６−オン，その製法及びその化合物を含む医薬
NO170580B (no)	1992-07-27	Analogifremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater
MXPA04012345A (es)	2005-02-25	Derivados de pirimidina 2,5-substituida como antagonistas ix del receptor ccr-3.